Dalrada Health’s cerVIA™ Test Kit Enables Immediate Results with Second Cervical Cancer Screening Study Amid COVID-19 Restrictions

Rhea-AI Summary

Dalrada Corporation (OTCQB: DFCO) has successfully completed a second clinical trial of its cerVIA™ kit for cervical cancer screening in India, involving 100 women. The study faced delays due to COVID-19, with results published in the IJOPARB Journal. This trial showed the kit's accuracy at 91%, contributing to a significant public health goal: the WHO's aim to eliminate cervical cancer by 2030. The cerVIA™ kit is designed to enhance accessibility and reduce hospital visits, operational during a time when cancer screenings have notably declined globally.

Positive

• Successful completion of a second clinical trial for the cerVIA™ kit.
• The kit demonstrated an accuracy rate of 91% for cervical cancer screening.
• Addresses a significant public health issue with the WHO's goal of eliminating cervical cancer by 2030.

Negative

• Initial clinical study delays due to the COVID-19 pandemic.

SAN DIEGO--(BUSINESS WIRE)-- Dalrada Corporation (OTCQB: DFCO, "Dalrada"), an innovator in healthcare, green energy, and technology, today announced that the Company completed a second clinical trial on its patent-pending cerVIA™ (visual inspection with acetic acid) kit used to screen for cervical cancer, allowing preventative measures in India with one hundred women. The second clinical study was significantly delayed due to COVID-19, and research data is now published in the perinatology and reproductive biology IJOPARB Journal article "Experience of Conducting Cervical Cancer Screening During Covid-19 Pandemic."

Around the world, amid COVID-19 pandemic fears, cancer screening services were paused, and patients postponed preventative healthcare screenings. Research by hospitals participating in the National Cancer Grid reveals a more than 60% reduction in outpatients in India. Across all cancers such as breast, cervix, colon, lung, and prostate, cancer screening rates declined by 60 to 80% compared to pre-pandemic screening rates (Source: Bakouny et al.).

Dr. Payal Keswarpu, Dalrada Health's Chief Medical Officer, who led the cervical cancer screening study, shares, "Innovative tests and healthcare delivery can help restart screening services to reach the goal set by the WHO, to eliminate cervical cancer by 2030."

Cervical cancer contributes to a significant number of cancer cases every year, especially in developing countries with limited medical resources. Every year a total of 569,847 new cases of cervical cancer are detected globally, with approximately 311,365 deaths. About 85% of these deaths occurred in low and middle-income countries. In India, there are about 75,000 new cases detected annually. (Source: IJOPARB Journal)

Dr. Keswarpu continues, "We could offer screening services in our hospital without crowding and maintaining social distance. The VIA kit was helpful; we always had the necessary items to conduct the test faster, reducing patient exposure time in the hospital. Also, adopting VIA as a screening procedure helped us reduce hospital visits for the women by providing instant results and decisions on next steps."

A test's accuracy in identifying individuals without a condition or characteristic is specificity.

Data from the first cervical cancer clinical study conducted in India revealed that cerVIA™ was 96.8% specific.

In the second preventive cervical cancer screening study conducted in India, one hundred women ages 31-65 were screened with Pap smear and VIA using the cerVIA™ kit. The second clinical study data reveals VIA's accuracy at 91%.

Developed by Dalrada Health, the patent-pending cerVIA™ Kit consists of standardized components needed to perform a VIA test on the cervix with all active ingredients sourced from FDA or ISO-approved facilities.

As the pandemic continues, innovative approaches to restoring practitioner-patient engagements include telehealth consultations, accessible diagnostic tests, and care closer to home.

Dr. Keswarpu adds, "One such innovation is the VIA Kit, which enables quick examination compared to standard preparation time of getting all necessary instruments, disposables, and reagents prepared. This approach will help in less time spent in a healthcare facility. In addition, there is no risk of cross-infection between patients, as all items are single-use for one patient."

Dalrada continuously creates innovative, impactful solutions to address the complex challenges of today and the future. To learn more about Dalrada Corporation and Dalrada Health, please visit www.Dalrada.com and www.DalradaHealth.com.

About Dalrada (DFCO)

Dalrada drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible.

The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Established in 1982, Dalrada has since grown its footprint to include the unique business divisions: Dalrada Health, Dalrada Precision, and Dalrada Technologies. For more information, please visit www.dalrada.com.

Disclaimer

Statements in this press release are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations regarding these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the US Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005372/en/

Denise Mahaffey

858.283.1253

inquiries@dalrada.com

Source: Dalrada Corporation

FAQ

What were the results of Dalrada Corporation's second clinical trial for the cerVIA™ kit?

The second clinical trial showed an accuracy rate of 91% for cervical cancer screening in India.

How does the cerVIA™ kit contribute to cervical cancer screening in India?

The cerVIA™ kit facilitates cervical cancer screening with high accuracy and helps reduce hospital visits during the ongoing pandemic.

What is the significance of the clinical trial for Dalrada Corporation (DFCO)?

This clinical trial is significant as it supports WHO's goal to eliminate cervical cancer by 2030 and addresses a decline in cancer screening due to COVID-19.

What challenges did Dalrada face during the clinical trial of the cerVIA™ kit?

The clinical trial experienced significant delays due to the COVID-19 pandemic.